Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis
暂无分享,去创建一个
G. Argenziano | G. Fabbrocini | M. Megna | C. Guarneri | M. Musumeci | P. Amerio | A. Balato | C. De Simone | G. Micali | L. Bianchi | G. Babino | G. Gualdi | S. Cannavò | L. Pescitelli | F. Prignano | A. Offidani | M. Esposito | S. Ribero | A. Campanati | M. Fargnoli | F. Rongioletti | G. Caldarola | A. Chiricozzi | G. Damiani | L. Stingeni | G. Malara | K. Hansel | P. Malagoli | S. Zanframundo | F. Bardazzi | A. Conti | G. Odorici | P. Dapavo | A. Raimondo | F. Ferrara | E. Scala | R. Fidanza | C. Mugheddu | C. Trifirò
[1] A. Balato,et al. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study , 2019, American Journal of Clinical Dermatology.
[2] G. Fabbrocini,et al. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1‐year period , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.
[3] S. Feldman,et al. Treatment decisions in psoriasis. , 2019, Journal of comparative effectiveness research.
[4] L. Atzori,et al. Biologics exposure during pregnancy and breastfeeding in a psoriasis patient , 2019, Dermatologic therapy.
[5] G. Varigos,et al. Baseline patients’ characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments , 2018, The Australasian journal of dermatology.
[6] G. Fabbrocini,et al. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows , 2018, Front. Immunol..
[7] M. Romanelli,et al. Elderly psoriatic patients under biological therapies: an Italian experience , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[8] M. Megna,et al. Real‐life effectiveness of biological drugs on psoriatic difficult‐to‐treat body regions: scalp, palmoplantar area and lower limbs , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] K. Payne,et al. Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength , 2017, The Journal of investigative dermatology.
[10] Shuai Xu,et al. Potential impact of biologics and emerging therapies for psoriasis and atopic dermatitis on future fertility: Reassurance to patients but more data are needed , 2017, Journal of the American Academy of Dermatology.
[11] N. Balato,et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders , 2017, Expert opinion on biological therapy.
[12] L. Naldi,et al. Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[13] L. Naldi,et al. Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry , 2017, The British journal of dermatology.
[14] M. Megna,et al. Soccer helps in controlling the development of psoriasis in Italian second league players , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[15] Nilendu Sarma. Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis , 2017, Indian journal of dermatology.
[16] A. Kimball,et al. Update on biologic safety for patients with psoriasis during pregnancy , 2017, International journal of women's dermatology.
[17] R. Althin,et al. Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients , 2017, BioDrugs.
[18] M. Megna,et al. Psoriasis in elderly and non-elderly population: clinical and molecular features. , 2016, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.
[19] M. Megna,et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2‐year period , 2016, Clinical and experimental dermatology.
[20] J. Erickson,et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.
[21] M. Megna,et al. Psoriasis and sport: a new ally? , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[22] Z. Adamski,et al. Factors affecting response to biologic treatment in psoriasis , 2014, Dermatologic therapy.
[23] J. Schmitt,et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[24] D. Terris,et al. Matching physicians’ treatment recommendations to patients’ treatment preferences is associated with improvement in treatment satisfaction , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[25] M. Eriksson,et al. The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men , 2013, PloS one.
[26] Rosa Parisi,et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. , 2013, The Journal of investigative dermatology.
[27] Nasir Umar,et al. Outcomes associated with matching patients' treatment preferences to physicians' recommendations: study methodology , 2012, BMC Health Services Research.
[28] A. Menter,et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. , 2010, Journal of the American Academy of Dermatology.
[29] M. Lebwohl,et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) , 2008, The Lancet.
[30] A. Kimball,et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.
[31] B. Evengård,et al. “The Laundry Bag Project”– unequal distribution of dermatological healthcare resources for male and female psoriatic patients in Sweden , 2008, International journal of dermatology.
[32] F. Taroni,et al. The Italian health-care system. , 2005, Health economics.
[33] E. Chung,et al. Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.
[34] Mark Lebwohl,et al. Psoriasis , 1906, The Lancet.
[35] K. Kragballe,et al. Experience of Being Young With Psoriasis: Self-Management Support Needs , 2018, Qualitative health research.
[36] E. Edson-Heredia,et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. , 2014, The Journal of investigative dermatology.